|Bid||69.01 x 900|
|Ask||69.63 x 800|
|Day's range||69.31 - 70.43|
|52-week range||56.56 - 73.34|
|Beta (5Y monthly)||0.36|
|PE ratio (TTM)||11.90|
|Earnings date||02 Feb 2022 - 07 Feb 2022|
|Forward dividend & yield||2.84 (4.08%)|
|Ex-dividend date||14 Dec 2021|
|1y target est||76.42|
Here's why they chose Vertex Pharmaceuticals (NASDAQ: VRTX), Gilead Sciences (NASDAQ: GILD), and Beam Therapeutics (NASDAQ: BEAM). Prosper Junior Bakiny (Vertex Pharmaceuticals): Shares of Vertex Pharmaceuticals, a biotech that focuses on developing treatments for rare diseases, have significantly lagged the market over the past year.
Amazon's (AMZN) AWS is chosen by Gilead Sciences as the preferred cloud provider.
The Zacks Analyst Blog Highlights: Accenture, Raytheon, Becton, Dickinson and Co, Boeing and Gilead Sciences